Silvina Mastaglia1,2, Dana Watson1, Natalia Bello3, Vanesa Fridman3, Daniel Stecher3, Beatriz Oliveri1,2. 1. Osteoporosis and Metabolic Bone Diseases Laboratory, Institute of Immunology, Genetics, and Metabolism (INIGEM) CONICET - UBA, Buenos Aires, Argentina. 2. Researcher of the National Council for Scientific and Technologic Research (CONICET), Buenos Aires, Argentina. 3. Infectology Division, Department of Internal Medicine, Hospital de Clínicas, University of Buenos Aires, Buenos Aires, Argentina.
Abstract
Vitamin D has immunomodulating properties. The nuclear receptor for vitamin D is expressed in several immune cells, which convert 25-hydroxyvitamin D (25OHD) to the active form 1,25 hydroxyvitamin D [1,25(OH)2 D]. Under conditions of infection, 1,25(OH)2 D promotes production of cathelicidin (an antimicrobial peptide) in monocytes and activated macrophages. In vitro studies have shown the ability of cathelicidin to inhibit replication of human immunodeficiency virus (HIV-1) in T CD4 lymphocytes and macrophages. OBJECTIVE: To evaluate vitamin D levels and their impact on mineral metabolism in HIV infected patients. MATERIALS AND METHODS: Seventy-four clinical records of HIV/AIDS patients seen at the outpatients clinic were reviewed. The following data were collected: age, sex, time since diagnosis of HIV, HIV-1 viral load, CD4 counts (absolute value and percentage), and mineral metabolism determinations: 25OHD, intact parathormone (iPTH); serum calcium (sCa); serum phosphorus (sP) and serum crosslaps (sCTX). Vitamin D levels were stratified as follows: optimal: ≥30ng/ml; insufficient: 21-29ng/ml; moderately deficient: 20≥ -25OHD- >10 ng/ml and severely deficient ≤10 ng/ml. RESULTS: Fifty-five clinical records were included; 82% of patients had 25OHD levels below 30ng/ml (insufficient: 23.6%, moderately deficient: 36.4%; and severely deficient: 21.8%). A significantly higher serum PTH levels in the moderately and severely deficient groups than in the optimal and insufficient groups was observed (p<0.05 and p<0.03 respectively). A weak negative correlation was observed between serum 25OHD and PTH levels (r=-0.268; p<0.004). CONCLUSION: Sub-optimal vitamin D levels are frequently observed in HIV/AIDS patients on antiretroviral therapy (ART). Systematic assessment of mineral metabolism is considered necessary in HIV/AIDS positive patients.
Vitamin D has immunomodulating properties. The nuclear receptor for vitamin D is expressed in several immune cells, which convert 25-hydroxyvitamin D (25OHD) to the active form 1,25 hydroxyvitamin D [1,25(OH)2 D]. Under conditions of infection, 1,25(OH)2 D promotes production of cathelicidin (an antimicrobial peptide) in monocytes and activated macrophages. In vitro studies have shown the ability of cathelicidin to inhibit replication of human immunodeficiency virus (HIV-1) in T CD4 lymphocytes and macrophages. OBJECTIVE: To evaluate vitamin D levels and their impact on mineral metabolism in HIV infectedpatients. MATERIALS AND METHODS: Seventy-four clinical records of HIV/AIDSpatients seen at the outpatients clinic were reviewed. The following data were collected: age, sex, time since diagnosis of HIV, HIV-1 viral load, CD4 counts (absolute value and percentage), and mineral metabolism determinations: 25OHD, intact parathormone (iPTH); serum calcium (sCa); serum phosphorus (sP) and serum crosslaps (sCTX). Vitamin D levels were stratified as follows: optimal: ≥30ng/ml; insufficient: 21-29ng/ml; moderately deficient: 20≥ -25OHD- >10 ng/ml and severely deficient ≤10 ng/ml. RESULTS: Fifty-five clinical records were included; 82% of patients had 25OHD levels below 30ng/ml (insufficient: 23.6%, moderately deficient: 36.4%; and severely deficient: 21.8%). A significantly higher serum PTH levels in the moderately and severely deficient groups than in the optimal and insufficient groups was observed (p<0.05 and p<0.03 respectively). A weak negative correlation was observed between serum 25OHD and PTH levels (r=-0.268; p<0.004). CONCLUSION: Sub-optimal vitamin D levels are frequently observed in HIV/AIDSpatients on antiretroviral therapy (ART). Systematic assessment of mineral metabolism is considered necessary in HIV/AIDS positive patients.
Entities:
Keywords:
25-hydroxyvitamin D; HIV; mineral metabolism
Authors: Peter Bergman; Lilian Walter-Jallow; Kristina Broliden; Birgitta Agerberth; Johan Söderlund Journal: Curr HIV Res Date: 2007-07 Impact factor: 1.581
Authors: Christine N Dao; Pragna Patel; E Turner Overton; Frank Rhame; Sherri L Pals; Christopher Johnson; Timothy Bush; John T Brooks Journal: Clin Infect Dis Date: 2011-02-01 Impact factor: 9.079
Authors: Tian-Tian Wang; Frederick P Nestel; Véronique Bourdeau; Yoshihiko Nagai; Qiuyu Wang; Jie Liao; Luz Tavera-Mendoza; Roberto Lin; John W Hanrahan; Sylvie Mader; John H White; John H Hanrahan Journal: J Immunol Date: 2004-09-01 Impact factor: 5.422
Authors: Nicolas J Mueller; Christoph A Fux; Bruno Ledergerber; Luigia Elzi; Patrick Schmid; Thanh Dang; Lorenzo Magenta; Alexandra Calmy; Athanasios Vergopoulos; Heike A Bischoff-Ferrari Journal: AIDS Date: 2010-05-15 Impact factor: 4.177
Authors: S Vasikaran; R Eastell; O Bruyère; A J Foldes; P Garnero; A Griesmacher; M McClung; H A Morris; S Silverman; T Trenti; D A Wahl; C Cooper; J A Kanis Journal: Osteoporos Int Date: 2010-12-24 Impact factor: 4.507
Authors: Juliana Mendes Abreu; Amanda B B Nogueira; Mariana M Villela; Denise M Módolo; Thaís C Panaro; Sérgio Setubal; Luiz Guillermo C Velarde; Giovanna A B Lima; Rubens A da Cruz Filho; Debora V Soares Journal: Arch Osteoporos Date: 2022-03-05 Impact factor: 2.617
Authors: Paulo C Gregório; Sergio Bucharles; Regiane S da Cunha; Tárcio Braga; Ana Clara Almeida; Railson Henneberg; Andréa E M Stinghen; Fellype C Barreto Journal: Clinics (Sao Paulo) Date: 2021-02-22 Impact factor: 2.365